Magenta Therapeutics Inc. (MGTA)
0.70
-0.06 (-7.69%)
At close: Sep 11, 2023, 8:00 PM
-7.69% (1D)
| Bid | n/a |
| Market Cap | 42.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -67.32M |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -0.6083478260869565 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 375,912 |
| Avg. Volume (20D) | 247,981 |
| Open | 0.71 |
| Previous Close | 0.76 |
| Day's Range | 0.69 - 0.76 |
| 52-Week Range | 0.32 - 1.81 |
| Beta | 2.11 |
About MGTA
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD4...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 67
Stock Exchange NASDAQ
Ticker Symbol MGTA
Website https://www.magentatx.com